阿托伐他汀联合氯吡格雷治疗短暂性脑缺血发作的疗效及对患者血浆超敏C反应蛋白与脂蛋白相关磷脂酶A_2的影响  

Effect of Atorvastatin Combined with Clopidogrel to Treat Transient Ischemic Attack on High Sensitive C-Reactive Protein in Plasma and Lipoprotein-Phospholipase A_2 of Patients

作　　者：娄卫东 李赵梅 谢紫明 

机构地区：[1]龙泉市人民医院神经内科,浙江龙泉323700

出　　处：《药物流行病学杂志》2015年第7期391-393,共3页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:观察阿托伐他汀联合氯吡格雷治疗短暂性脑缺血发作(TIA)的临床疗效,以及对患者血浆超敏C反应蛋白(hs-CRP)和脂蛋白相关磷脂酶A2(Lp-PLA2)的影响。方法:80例TIA患者根据住院号分为观察组与对照组,每组各40例。两组患者均予常规治疗;观察组在此基础上加用阿托伐他汀片20 mg,po qd,氯吡格雷片75 mg,po qd。两组疗程均为4周。观察两组疗效及药品不良反应,比较两组患者治疗前后血浆hs-CRP及Lp-PLA2水平。结果:治疗4周后,两组患者血浆hs-CRP、Lp-PLA2水平均较治疗前降低(P<0.05或P<0.01),且观察组降低幅度大于对照组(P<0.05);观察组总有效率高于对照组(P<0.05)。两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿托伐他汀联合氯吡格雷治疗TIA能提高临床疗效,且安全性好,其作用机制与降低血浆hs-CRP与Lp-PLA2水平密切相关。Objective： To discuss the influence and curative effect of atorvastatin combined with clopidogrel to treat transient ischemic attack （TIA） on high sensitive C-reactive protein （hs-CRP） and Lipoprotein-phospholipase A2 （Lp -PLA2 ） in plasma of patients. Methods：80 cases of patients with TIA were divided into observation group and control group at random. The patients in two groups were given routine treatment, the patients in observation group were additionally given atorvastatin tablets 20mg and clopidogrel tablets 75mg, once a day, through the mouth for a course of treatment for 4 weeks. The curative effect and adverse drug reactions of patients in two groups were observed, and the changes of plasma level of hs-CRP and Lp-PLA2of patients in two groups were compared. Results：After 4 weeks＇ medical treatment, the hs- CRP and Lp-PLA2 levels in plasma of patients in two groups declined than before （P 〈 0.05 and P 〈 0.01 ）, and the improvement rates of patients in observation group were much higher than those in control group （P 〈 0.05）. After 4 weeks＇ medical treatment, the total efficiency of treatment of patients in observation group was much higher than that in control group （P 〈 0.05）. After comparing the occurrences of adverse drug reactions of patients in two groups during the medical treatment, no statistical differences appeared （ P 〉 0.05 ）. Conclusion： The application of atorvastatin combined with clopidogrel to treat TIA can effectively improve the curative effect, whose mechanism of action had close effect on reducing the hs-CRP and Lp-PLA2 levels in plasma with low occurrence of adverse reactions.

关 键 词：短暂性脑缺血发作 阿托伐他汀 氯吡格雷 超敏C反应蛋白 脂蛋白相关磷脂酶A2 

分 类 号：R972[医药卫生—药品]